Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 54 |
| Active Pipeline (Recruiting Now) | 29 (13) |
| Completed vs Stopped Early | 17 / 8 (14.8%) |
| Median Closed Actual Enrollment | 103 participants |
| Physical Hospital Site Disclosure | 99.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital de La Santa Creu I Sant Pau | Barcelona | 9 |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | 7 |
| Fakultni nemocnice Brno | Brno, Moravia | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07287982 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pedi | Phase II | RECRUITING |
| NCT06544499 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia | Phase III | RECRUITING |
| NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Phase III | RECRUITING |
| NCT07570316 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease | Phase III | RECRUITING |
| NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the argenx Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.